logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer

< Back

Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer

Drugs

Cancer and Palliative Care

June 2021


Darolutamide in addition to docetaxel and androgen deprivation therapy (ADT) is in clinical development for the treatment of patients with metastatic hormone-sensitive prostate cancer. Prostate cancer affects the prostate (a small gland in the pelvis only found in men), but symptoms generally do not appear until the prostate is large enough to affect the urethra (the tube connecting the bladder to outside the body). Metastatic prostate cancer is when the cancer spreads to another part of the body. Common symptoms of metastatic prostate cancer include bone pain and fatigue.
Androgen receptors promote prostate cancer growth, darolutamide is a nonsteroidal androgen receptor inhibitor and can prevent cancer growth. Docetaxel in combination with ADT are commonly used in practice, the addition of darolutamide (taken orally) may improve survival and offer an additional treatment option for those patients with metastatic hormone-sensitive prostate cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts